

PEDIATRIC

BRAIN

ACNS 0332: Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in other than Average Risk Medulloblastoma/PNET Patients.

<https://clinicaltrials.gov/ct2/show/NCT00392327?term=0332&rank=6>

ACNS 02B3: Children's Oncology Group (COG) Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens.

<https://clinicaltrials.gov/ct2/show/NCT00919750?term=02b3&rank=1>

ACNS 0831: Randomized Trial of Post-Radiation Chemotherapy in Patients with newly Diagnosed Ependymoma Ages 1-21 Years: A Group wide Phase III Study.

<https://clinicaltrials.gov/ct2/show/NCT01096368?term=ACNS+0831&rank=1>

ACNS 1123: Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS-GCT).

<https://clinicaltrials.gov/ct2/show/NCT01602666?term=acns+1123&rank=1>

COMPANION STUDIES

ACCRN 07: Protocol for the Enrollment on the Official COG Registry, the Childhood Cancer Research Network (CCRN).

<https://clinicaltrials.gov/ct2/show/NCT01117168?term=Protocol+for+the+Enrollment+on+the+Official+COG+Registry&rank=1>

POG 9902: COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol.

<https://clinicaltrials.gov/ct2/show/NCT00919269?term=pog+9902&rank=1>



ABTR 01B1: COG Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors.

<https://clinicaltrials.gov/ct2/show/NCT00898079?term=abtr+01b1&rank=2>

ALTE 07C1: Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer.

<https://clinicaltrials.gov/ct2/show/NCT00772200?term=ALTE+07C1&rank=1>

ALTE 1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial

<https://clinicaltrials.gov/ct2/show/NCT02717507?term=ALTE+1621&rank=1>

CANCER CONTROL

ALTE 05N1: Umbrella Long-Term Follow-Up Protocol.

<https://clinicaltrials.gov/ct2/show/NCT00736749?term=ALTE+05N1&rank=1>

NEUROBLASTOMA & OTHER EMBRYONAL TUMORS

ANBL 00B1: Neuroblastoma Biology Studies.

<https://clinicaltrials.gov/ct2/show/NCT01117168?term=COG+registry&rank=1>

ANBL1221: Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma.

<https://clinicaltrials.gov/ct2/show/NCT01767194?term=ANBL1221&rank=1>

ANBL1232: Utilizing Response and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma.

<https://clinicaltrials.gov/ct2/show/NCT02176967?term=ANBL1232&rank=1>



LYMPHOMAS/HODGKIN'S DISEASE

AHOD1331: Randomized Study of Brentuximab Vedotin (SGN-35, IND # 117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents.

<https://clinicaltrials.gov/ct2/show/NCT02166463?term=AHOD1331&rank=1>

ANHL12P1: Randomized Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC# 749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL).

<https://clinicaltrials.gov/ct2/show/NCT01979536?term=ANHL12P1&rank=1>

NATIONAL WILM'S TUMOR STUDY

POG 9442: National Wilms Tumor Late Effects Study.

<https://clinicaltrials.gov/ct2/show/NCT00736749?term=ALTE05N1&rank=1>

AREN 03B2: Renal tumors Classification, Biology, and Banking Study.

<https://clinicaltrials.gov/ct2/show/NCT00898365?term=AREN03B2&rank=1>

HEPATOBLASTOMA TUMORS

AHEP 0731: Treatment of Children with All Stages of Hepatoblastoma.

<https://clinicaltrials.gov/ct2/show/NCT00980460?term=AHEP+0731&rank=1>

MULTI DISEASE SITES

APEC 14B1: The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study.

<https://clinicaltrials.gov/ct2/show/NCT02402244?term=14B1&rank=1>

BONE & SOFT TISSUE SARCOMAS

AOST 06B1: A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens.



<https://clinicaltrials.gov/ct2/show/NCT00899275?term=AOST+06B1&rank=1>

AEWS 07B1: A Children's Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens.

<https://clinicaltrials.gov/ct2/show/NCT00899990?term=AEWS+07B1&rank=1>

AEWS 1031: Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma.

<https://clinicaltrials.gov/ct2/show/NCT01231906?term=AEWS+1031&rank=1>

AEWS 1221: Randomized Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND # 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma.

<https://clinicaltrials.gov/ct2/show/NCT02306161?term=AEWS+1221&rank=1>

AOST 1321: Phase 2 Study of Denosumab (IND#127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma

<https://clinicaltrials.gov/ct2/show/NCT02470091?term=AOST+1321&rank=1>

ARST 1321: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS), a Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)

<https://clinicaltrials.gov/ct2/show/NCT02180867?term=ARST+1321&rank=1>

LEUKEMIA (ALL)

AALL 05B1: COG Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens.

<https://clinicaltrials.gov/ct2/show/NCT00897325?term=AALL+05B1&rank=1>

AALL 08B1: Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL).

<https://clinicaltrials.gov/ct2/show/NCT01142427?term=AALL+08B1&rank=2>



AALL 0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy).

<https://clinicaltrials.gov/ct2/show/NCT01190930?term=AALL+0932&rank=1>

AALL 1131: Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (B-ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum – Including a stratum evaluating Dasatinib (IND# 73789, NSC# 732517) in patients w/ Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

<https://clinicaltrials.gov/ct2/show/NCT02883049?term=AALL+1131&rank=1>

AALL 1231: Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy).

<https://clinicaltrials.gov/ct2/show/NCT02112916?term=AALL+1231&rank=1>

AALL 1331: Risk-Stratified Randomized Testing of Blinatumomab (IND# 117467, NSC# 765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

<https://clinicaltrials.gov/ct2/show/NCT02101853?term=AALL+1331&rank=1>

AALL 15P1: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial

LEUKEMIA (AML)

AAML 08B1: Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS).

<https://clinicaltrials.gov/ct2/results?term=AAML+08B1&Search=Search>

AAML 1031: Randomized Trial for Patients with de novo AML Using Bortezomib and Sorafenib (IND# 114480; NSC# 681239; NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD.

<https://clinicaltrials.gov/ct2/show/NCT01371981?term=AAML+1031&rank=1>



AAML 1331: A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

<https://clinicaltrials.gov/ct2/show/NCT02339740?term=AAML+1331&rank=1>

AAML 1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome (DS).

<https://clinicaltrials.gov/ct2/show/NCT02521493?term=AAML+1531&rank=1>

